Figure 3 | Scientific Reports

Figure 3

From: Interplay between IL6 and CRIM1 in thiopurine intolerance due to hematological toxicity in leukemic patients with wild-type NUDT15 and TPMT

Figure 3

Distribution of the last-cycle 6-MP DIP for pediatric patients with ALL according to NUDT15, TPMT, CRIM1, and IL6 pharmacogenetic subgroups (N = 320). Green circles depict NUDT15 and TPMT metabolism phenotypes, and blue and orange circles represent CRIM1 rs3821169 and IL6 rs13306435 genotype subgroups, respectively. Of the 320 patients, 115 with no pharmacogenetic variants exhibited higher 6-MP DIPs (71.31%) than 72 NUDT15 (47.14%), 9 TPMT (56.56%), 147 CRIM1 (57.89%), and 25 IL6 (DIP = 44.47%) non-WTs. Subjects with both CRIM1 and IL6 variants (N = 10, 3.13%) exhibited the lowest DIPs (9.77–32.68%, in red numbers). Numbers are the number of subjects and 6-MP DIPs (mean ± SD). ALL acute lymphoblastic leukemia, WT wild-type, non-WT non-wild-type (i.e., poor- or intermediate thiopurine-metabolizing sub-groups of NUDT15 and TPMT carriers), DIP dose intensity percentage, SD standard deviation.

Back to article page